Lesson
HPA Axis, Circadian Timing, and Stress
Adrenal glucocorticoid exposure begins with a pulsatile, circadian control system that changes rapidly during stress and is suppressed by exogenous steroid feedback.
- CRH and vasopressin
- ACTH
- MC2R and MRAP
- Circadian cortisol
- Negative feedback
Hypothalamus drives pituitary ACTH and adrenal cortisol synthesis
Cortisol output rises near waking and during physiologic stress
Endogenous and exogenous glucocorticoids reduce CRH and ACTH
Trace the endocrine signal
Hypothalamic CRH and vasopressin stimulate pituitary corticotrophs to release ACTH. ACTH binds melanocortin 2 receptors in the adrenal cortex, with MRAP required for normal receptor function, and promotes cortisol synthesis and adrenal trophic support.
Respect time and stress
Cortisol secretion is pulsatile and usually highest near waking and lowest around midnight. Illness, surgery, trauma, hypoglycemia, and other stressors increase demand, so a single cortisol value must be interpreted through time, stress, binding, and exogenous exposure.
Close the feedback loop
Cortisol and synthetic glucocorticoids reduce CRH and ACTH signaling. Sustained feedback can reduce adrenal stimulation and eventually adrenal responsiveness, which is why abrupt withdrawal after sufficient exposure can reveal glucocorticoid deficiency.
Quick check
Lesson
Adrenal Cortex Zones and Hormone Outputs
The adrenal cortex is chemically organized by zone, with enzyme expression and regulators directing cholesterol toward mineralocorticoids, glucocorticoids, or adrenal androgens.
- Zona glomerulosa
- Zona fasciculata
- Zona reticularis
- Angiotensin II and potassium
- ACTH
Angiotensin II and potassium regulate aldosterone
ACTH supports cortisol synthesis
ACTH contributes to adrenal androgen production
Assign the glomerulosa
The outer zona glomerulosa produces aldosterone. Angiotensin II and potassium are principal regulators, and aldosterone synthase completes the mineralocorticoid pathway. This zone lacks meaningful CYP17A1 activity, which limits cortisol and androgen synthesis.
Assign the fasciculata
The middle zona fasciculata produces cortisol under strong ACTH regulation. Its enzyme pattern supports 17-hydroxylation and 11-beta-hydroxylation but not the final aldosterone-synthase sequence.
Assign the reticularis
The inner zona reticularis produces DHEA, DHEA sulfate, androstenedione, and related adrenal androgens. ACTH contributes to regulation, while enzyme balance favors 17,20-lyase activity and androgen precursors.
Quick check
Lesson
Cholesterol and Adrenal Steroidogenesis
Every adrenal steroid begins with cholesterol, but mitochondrial transport and zone-specific enzymes determine whether the final product is cortisol, aldosterone, or an androgen precursor.
- StAR
- CYP11A1
- CYP17A1
- CYP21A2
- CYP11B1 and CYP11B2
Mitochondrial cholesterol becomes pregnenolone
Hydroxylation directs cortisol, mineralocorticoid, or androgen flow
Distinct mitochondrial enzymes complete cortisol or aldosterone
Enter the mitochondrion
StAR moves cholesterol to the inner mitochondrial membrane, where CYP11A1 removes the side chain to form pregnenolone. This is the common entry step for adrenal steroid synthesis and a key point of acute ACTH regulation.
Build the cortisol branch
CYP17A1 supports 17-hydroxylation, 3-beta-HSD creates the 3-keto-4-ene steroid pattern, CYP21A2 forms 11-deoxycortisol, and CYP11B1 completes cortisol synthesis. Each block changes both product and precursor flow.
Separate aldosterone and androgen branches
The glomerulosa directs progesterone through CYP21A2 and CYP11B2 toward aldosterone. In the reticularis, CYP17A1 17,20-lyase activity favors DHEA and androgen precursors. Shared early steps make pathway diversion clinically important.
Quick check
Lesson
Glucocorticoid Receptor Signaling
Glucocorticoids change cell behavior by entering cells, binding an intracellular receptor complex, moving to the nucleus, and altering transcription through direct and indirect mechanisms.
- NR3C1
- Heat-shock proteins
- GRE binding
- Transactivation
- Transrepression
Ligand changes a chaperone-associated receptor conformation
Activated receptor reaches chromatin and transcriptional machinery
Direct and indirect signaling changes inflammation and metabolism
Activate the receptor complex
Unbound glucocorticoid enters the cell and binds the glucocorticoid receptor, or NR3C1, within a chaperone-associated cytosolic complex. Ligand binding changes receptor conformation, releases selected chaperones, and promotes nuclear translocation.
Regulate genes directly
Receptor dimers can bind glucocorticoid response elements and recruit transcriptional coregulators. This transactivation contributes to metabolic programs, anti-inflammatory proteins, and many dose-limiting adverse effects.
Modify inflammatory networks
Ligand-bound receptor can also influence NF-kappa B, AP-1, chromatin, and other transcriptional machinery. These interactions reduce inflammatory mediators, but a simple transactivation-versus-transrepression split does not fully explain clinical efficacy or toxicity.
Quick check
Lesson
Mineralocorticoid Receptor and 11-Beta-HSD2
Aldosterone achieves tissue selectivity not because cortisol cannot bind the mineralocorticoid receptor, but because selected tissues enzymatically protect that receptor from cortisol.
- NR3C2
- Aldosterone
- Cortisol competition
- 11-beta-HSD2
- Sodium and potassium handling
Both can bind the mineralocorticoid receptor with high affinity
Local cortisol inactivation preserves aldosterone selectivity
MR signaling promotes sodium retention and potassium secretion
Recognize receptor overlap
The mineralocorticoid receptor, or NR3C2, can bind aldosterone and cortisol with high affinity. Circulating cortisol is far more abundant, so receptor selectivity requires local enzymatic control rather than ligand affinity alone.
Protect the receptor
In aldosterone-sensitive epithelia, 11-beta-HSD2 converts active cortisol to cortisone, which has little mineralocorticoid receptor activity. Inhibition or deficiency of this enzyme allows cortisol to drive sodium retention, potassium loss, and hypertension.
Translate signaling into transport
Activated mineralocorticoid receptor increases epithelial sodium transport and supports potassium and hydrogen secretion in the distal nephron. Fludrocortisone exploits this pathway, while glucocorticoids differ markedly in residual mineralocorticoid activity.
Quick check
Lesson
Corticosteroid Scaffold and Structure-Activity Relationships
Small changes to the four-ring steroid scaffold can markedly shift receptor potency, mineralocorticoid activity, metabolic stability, and duration.
- 3-Keto-4-ene motif
- 11-beta-hydroxyl
- 1,2 double bond
- 9-alpha-fluorine
- 6 and 16 substitutions
The active alcohol supports glucocorticoid receptor recognition
These changes raise glucocorticoid selectivity and reduce salt retention
Potency rises while C16 substitution can suppress mineralocorticoid activity
Keep the active glucocorticoid pattern
The corticosteroid nucleus contains four fused rings. A 3-keto-4-ene pattern, the 11-beta-hydroxyl group, and the 17 and 21 oxygenated side-chain region contribute to glucocorticoid recognition. Oxidation of 11-beta-hydroxyl creates a less active 11-keto prodrug in selected pairs.
Increase glucocorticoid selectivity
A 1,2 double bond, as in prednisolone, increases glucocorticoid potency and reduces relative mineralocorticoid activity. A 6-alpha-methyl group, as in methylprednisolone, further reduces salt-retaining activity.
Use fluorine and C16 substitution carefully
A 9-alpha-fluorine strongly increases receptor potency and can increase mineralocorticoid activity. C16 methyl or hydroxyl substitution can counter mineralocorticoid activity while retaining potent, often long glucocorticoid action, as seen in dexamethasone, betamethasone, and triamcinolone.
Quick check
Lesson
The Clinical Glucocorticoid Family
Hydrocortisone, prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone, and betamethasone occupy different positions on the potency, duration, and mineralocorticoid spectrum.
- Short acting
- Intermediate acting
- Long acting
- Mineralocorticoid activity
- Fludrocortisone
Endogenous-like exposure with meaningful mineralocorticoid activity
Flexible systemic anti-inflammatory exposure with varied activation
High potency and long action with little mineralocorticoid effect
Use short and intermediate agents deliberately
Hydrocortisone resembles endogenous cortisol and retains meaningful mineralocorticoid activity. Prednisone, prednisolone, methylprednisolone, and triamcinolone provide progressively different activation, potency, and salt-retaining profiles over an intermediate duration.
Reserve long-acting potency for a reason
Dexamethasone and betamethasone are highly potent, long acting, and have minimal mineralocorticoid activity. Their prolonged biologic effect can be useful, but it can also complicate titration, circadian replacement, and HPA recovery.
Separate mineralocorticoid replacement
Fludrocortisone is a strongly mineralocorticoid synthetic steroid with glucocorticoid activity at higher exposure. It is used when sodium-retaining hormone action is needed, not as a routine substitute for every anti-inflammatory glucocorticoid.
Quick check
Lesson
Activation, Disposition, and Local Delivery
Corticosteroid exposure depends on conversion between active and inactive forms, protein binding, hepatic metabolism, route, tissue esterification, and first-pass extraction.
- Prednisone activation
- Cortisone activation
- CBG and albumin
- CYP3A4
- Local and low-bioavailability delivery
Prednisone and cortisone require conversion to active alcohols
Disposition and interacting drugs alter free and total exposure
Route and first-pass extraction can reduce but not erase systemic effects
Activate 11-keto prodrugs
Prednisone requires conversion to prednisolone, and cortisone requires conversion to cortisol, largely through 11-beta-HSD1. Severe hepatic dysfunction or altered enzyme activity can make prodrug exposure less predictable than direct active-drug dosing.
Account for binding and metabolism
Cortisol and many synthetic glucocorticoids bind corticosteroid-binding globulin and albumin to different degrees. CYP3A4 contributes to metabolism of several agents, so strong inhibitors can raise systemic exposure and inducers can lower it.
Design delivery to limit exposure
Inhaled, intranasal, topical, intra-articular, and gut-targeted products can concentrate action near the disease site. High first-pass metabolism, as with budesonide, reduces swallowed systemic exposure, but nonoral routes can still suppress the HPA axis, especially at high dose, long duration, multiple routes, or with CYP3A4 inhibition.
Quick check
Lesson
Glucocorticoid Dose Equivalence and Conversion
Equivalence tables compare approximate anti-inflammatory exposure, but a safe conversion also accounts for schedule, duration, route, mineralocorticoid activity, and the disease being treated.
- Hydrocortisone 20 mg
- Prednisone 5 mg
- Methylprednisolone 4 mg
- Dexamethasone 0.75 mg
- Daily-dose conversion
Use a common approximate potency anchor
Scale the complete daily dose through equivalent units
Duration, route, mineralocorticoid action, and indication still differ
Use a common reference
A commonly used approximate anti-inflammatory equivalence is hydrocortisone 20 mg, prednisone or prednisolone 5 mg, methylprednisolone 4 mg, and dexamethasone 0.75 mg. Cortisone 25 mg is also often treated as approximately equivalent to hydrocortisone 20 mg.
Convert total daily exposure
Multiply the source total daily dose by the ratio of target-equivalent dose to source-equivalent dose. For example, methylprednisolone 32 mg daily corresponds approximately to prednisone 40 mg daily because each 4 mg of methylprednisolone maps to 5 mg of prednisone.
Name the limits
Equivalent anti-inflammatory doses do not create the same biologic duration, peak, mineralocorticoid activity, formulation behavior, or HPA effect. Conversion supports an initial plan, while indication, clinical response, and safety monitoring determine the final regimen.
Quick check
Lesson
Cumulative Exposure, HPA Suppression, and Withdrawal
Glucocorticoid harm is shaped by total exposure and susceptibility, while HPA recovery varies enough that taper decisions must combine disease control, duration, potency, route, symptoms, and endocrine context.
- Metabolic and cardiovascular toxicity
- Bone, eye, skin, muscle, and growth
- Infection and vaccination
- HPA suppression
- Taper principles
Multiple products and metabolic inhibitors can accumulate
Monitor metabolic, infectious, skeletal, ocular, and endocrine effects
Reduce faster above physiologic exposure and more slowly near recovery
Monitor the whole toxicity pattern
Systemic glucocorticoids can worsen glucose, blood pressure, fluid balance, mood, sleep, infection risk, bone loss, myopathy, skin fragility, cataract, glaucoma, and growth. Risk depends on dose and duration, but susceptible patients can experience important harm early.
Recognize hidden cumulative exposure
Oral, injected, inhaled, intranasal, topical, and ocular products can overlap. Long-acting agents, evening dosing, repeated courses, large local doses, multiple routes, and CYP3A4 inhibitors can increase suppression risk even when no single prescription appears extreme.
Taper for the right reason
Current endocrine guidance generally does not require tapering solely to protect the HPA axis after treatment shorter than three to four weeks. Long-term therapy is tapered only when the underlying disease permits, usually faster at supraphysiologic doses and more slowly near physiologic exposure, with education for stress and crisis symptoms when suppression is possible.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 104 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.